It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
Browsing: 1220
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.